The US Food and Drug Administration (FDA) has granted regenerative medicine advanced therapy (RMAT) designation to Beacon ...

Discover the importance of vision, genetic eye disorders, and RNA-based therapies for precision treatment in India and ...

Argus II is a novel healthcare technology that restores vision in RP patients. Improvements in visual acuity are expected to lead to improvements in patient self-confidence, decreasing their ...

The NPI-001 (N-acetylcysteine amide) tablets are a proprietary investigational therapy for the treatment of patients with ...

Retinal degeneration encompasses a range of ... Among these conditions, retinitis pigmentosa (RP) and age-related macular degeneration (AMD) are particularly prevalent. Recent advancements in ...

particularly those affected by retinitis pigmentosa. Research has also highlighted the challenges posed by the abnormal wiring of retinal cells in degenerate retinas. Studies have shown that the ...

The study populations comprised 24 patients with a STGD [12 M, 12 F; median age: 34 years (range: 13–64)] and 56 patients with RP [23 M, 33 F; median age: 45 years (range: 14–85)] referring to ...

The rationale is that MCO can restore the light-detecting function of retinal cells that are damaged in RP, regardless of the underlying mutation that has caused the disease. Approximately 100,000 ...

Genetic predisposition also plays a role, especially for individuals with a family history of retinal degenerative diseases like retinitis pigmentosa. Chronic diseases, such as diabetes and ...

Kaiser shared data from the phase 1 HELIOS trial that showed stability or improvement in diabetic retinopathy at 1 year after treatment with the implant. Patients also saw improvements in diabetic ...

Vision research. From Gannett Foundation: $40,000 and $31,390 to Baylor College of Medicine for genetic research on retinal dystrophies $106,000 to Harvard University and $101,751 to the University of ...